High myoglobin plasma samples risk being reported as falsely low due to antigen excess – follow up after a 2-year period of using a mitigating procedure
If the Roche Elecsys<sup>®</sup> Myoglobin assay is used according to the manufacturer, extremely high myoglobin samples risk being reported as only mildly elevated or near normal. This may affect clinical decisions. Thus, we suggest an AE mitigation procedure with automatic dilution of samples where myoglobin concentrations exceed 500 μg/L to mitigate this risk. Roche needs to take further actions to eliminate the consequences of the AE interference.
Authors
- Joakim Sandstedt (ORCID: https://orcid.org/0000-0002-6458-9550)
- Anders Olsson (ORCID: https://orcid.org/0000-0002-0976-9057)
- Manne Stenberg
- Karin Lundberg (ORCID: https://orcid.org/0000-0001-7625-964X)
- Esmira Becirevic
Institutions
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1515/cclm-2025-0409
- Primary Topic
- Clinical Laboratory Practices and Quality Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00